Skip to main content
Donate

Industry

News

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Ionis Pharmaceuticals today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. 

If you have questions about trial sites or participation, please reach out directly to Ionis at (844) 285-7172 or  IonisION582-CS2@clinicaltrialmedia.com 

Related

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome
Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roche.
IONIS REVEAL Phase 3 Clinical Trial Update
FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome

View All News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.